Top Biotech Stocks

However, we think Moderna is still in the process of building a moat, as multiple other firms could have the technology to compete, and the overall market opportunity remains unclear. To find undervalued biotech stocks, we turned to the Morningstar US Biotechnology Index. Group, Inc., including a minimum market capitalization of $200 million and an average daily trading volume of at least 100,000 shares.

While most investors fled for safer havens this week, biotech analysts were advising clients to take advantage of discounted stock prices. Another index fund, the XBI, which tracks smaller and mid-sized biotech companies, has lost almost 43% in the past year. The value of a widely followed biotech stock index fund, the IBB, is down 23% over the last year. But that doesn’t even tell the whole story because it’s dominated by bigger companies like Moderna, whose stock is benefiting, of course, mightily from its Covid vaccine. Get Started Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.

Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in oureditorial policy.

S&P Select Industry Indices Consultation on Constituent Weighting

« Things are cyclical. So, maybe it’s out of favor now but things will come back. And I think it will come back with a roar. » The issuer of the security must have « seasoned » on NASDAQ or another recognized market for at least 6 months; in the case of spin-offs, the operating history of the spin-off will be considered. The security must have a market capitalization of at least $200 million. The security U.S. listing must be exclusively on the NASDAQ National Market (unless the security was dually listed on another U.S. market prior to January 1, 2004 and has continuously maintained such listing). It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.

BBH tracks the MVIS US Listed Biotech 25 Index, an index of companies that develop, produce, market, and sell drugs based on genetic analysis and diagnostic equipment. The fund holds predominantly large-cap stocks and more than 90% of its holdings are U.S.-based companies. These ETFs own companies that focus on areas including biological services, and developing and commercializing products based on genetic engineering and genetic analysis.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Mergers and acquisitions are common in the biotech sector, which means that any of the most promising biotech companies could be acquired by their larger competitors. A deep pipeline is one thing, but at some point a company has to be able to bring a product to market. Completing clinical trials on human patients is only the first step. Nevertheless, getting a drug successfully through clinical trials is a good indicator that a product will come to market sooner rather than later. On the other hand, perhaps no other sector comes with so much risk.

Head-to-Head ETF Comparison

BOSTON — https://forex-world.net/ stocks staged a healthy rebound from Monday’s frightful plunge, with practically all of the large-cap pharmaceutical makers gaining at least 2%. Global Index Data Service offers a real-time data feed that consolidates all 45,000 Nasdaq indexes, as well as exchange-traded products valuation data and third-party partner data. Yee acknowledges that there have been some positive moves this year, but there were mostly for smaller-cap biotechs, with market capitalizations under $500 million.

Full BioNathan Reiff has been writing expert articles and news about financial topics such as investing and trading, cryptocurrency, ETFs, and alternative investments on Investopedia since 2016. Several of Regeneron’s drug development programs are focused on gaining approvals for new indications for already approved drugs. The company also is developing new drug candidates, notably including the experimental gene-editing therapy NTLA-2001, which Regeneron is developing in partnership with Intellia Therapeutics. Auvelity could be a blockbuster drug in treating depression, with peak annual sales — the highest dollar volume of sales per year projected by analysts — estimated at $2.6 billion.

Investing in biotech stocks can be one of the most profitable sectors for risk-tolerant investors. Biotech companies are engaged in research and development for chronic and life-threatening conditions. If these companies are able to successfully bring a product to market, its stock price can double, triple or move even higher. The metric calculations are based on U.S.-listed ETFs that are classified by ETF Database as being mostly exposed to a specific industry. If an ETF changes its industry classification, it will also be reflected in the investment metric calculations. The fund invests in primarily growth stocks of various market capitalizations.

• « Things are cyclical. So, maybe it’s out of favor now but things will come back. And I think it will come back with a roar. »
• And, unlike the speed at which Covid-19 vaccines were approved, this can also be a lengthy process.
• News about the safety or efficacy of one of the drugs produced by a large-cap biotech company can move its stock, but because the company has several drugs on the market, it’s not dependent on any particular one.
• However, due to the unprecedented assistance from the U.S. government through Operation Warp Speed , the growth in some biotech stocks was also an anomaly.
• That percentage has more than doubled over the past 50 years.
• Some brokerages, like Vanguard, offer this tool for account holders.

The scoring formula for online brokers and robo-advisors takes into Biotech stock index over 15 factors, including account fees and minimums, investment choices, customer support and mobile app capabilities. The world’s largest biotech and pharmaceutical companies are constantly racing to find new vaccines, treatments and cures. Investments, such as Biotechnology ETFs, on a wide range of criteria including expenses, performance, dividend yield and volatility. If an ETF’s industry classification changes, it will affect the dividend yield calculations. Biotech companies are having one of their worst stock-market runs in years, as rising interest rates, scientific setbacks and a slowdown in big pharma buyouts batter the sector.

Exclusive coverage and analysis of

Its biggest winner by far is Cabometyx, which is approved to treat renal cell carcinoma and hepatocellular carcinoma — the most common types of kidney cancer and liver cancer, respectively — as well as thyroid cancer. Some scientists believe that we’re in the golden age of biotechnology. Scientific advances are creating new and previously only imaginable ways to treat and prevent diseases. Analyst consensus is the average investment recommendation among Wall Street research analysts. MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.

Some might argue that biotech stocks — led by Moderna , BioNTech , Regeneron Pharmaceuticals and others — saved the world in 2020 as they launched vaccines and treatments to tackle an inescapable pandemic. “CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company’s proprietary platform specializes in CRISPR/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations. “Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

Financial Calendars

The highly regulated nature of the industry creates a unique set of pros and cons for investors. Below is a list of 10 of the best-performing biotech stocks in the New York Stock Exchange Arca Biotechnology Index. Biotech stocks are publicly traded ownership shares of companies that make medicines, vaccines and other biological products. The world may be recovering from the COVID-19 pandemic, but the need for medicine will never go away.

The process to get a product approved is lengthy and expensive. And just getting a product through clinical trials is not sufficient. And, unlike the speed at which Covid-19 vaccines were approved, this can also be a lengthy process. Another distinction between the two companies is that pharmaceutical companies spend a great deal of money in marketing and sales. On the other hand, biotech companies see their strength as being in research and development (R&D). This focus on R&D may cause biotech companies to raise capital which can dilute their share price even further.

First Trust NYSE Arca Biotechnology Index Fund

The industry includes smaller start-up companies with recent traction as well as large, well-established corporations that aim to develop a range of drugs and technologies. Many biotech companies have shifted their focus entirely or added COVID-19 vaccines and treatments to their product pipeline. Biotech stocks began soaring in the spring of 2020 as individual investors and hedge funds flocked to the sector amid intense attention on the race to develop new vaccines and drugs for Covid-19.

• “Beyond JAK inhibition, the recent approval of lymphoma drug Monjuvi in 2020 in the U.S. and 2021 in Europe also expands Incyte’s hematology portfolio, and studies are in progress testing the drug in earlier-stage patients.
• Early-stage biotech companies are prone to wild swings in revenue due to going from nearly no revenue to having a significant revenue stream once a drug is approved or a partnership with another company is reached.
• The use of living organisms differentiates biotechnology companies from pharmaceutical companies, which research and develop chemicals to invent drugs.
• If an ETF’s industry classification changes, it will affect the dividend yield calculations.
• Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

And that means that you should be looking for companies that have an ample cash reserve. It’s not uncommon for small-cap biotech firms to raise money through secondary share offerings. Companies that continually need to issue share offerings should raise a caution flag for investors. However, investors see the same speculative activity occur with biotech firms that are researching treatments for areas such as cancer, AIDS, heart disease and neurological conditions.

Our estimates are based on past market performance, and past performance is not a guarantee of future performance. Here are the top biotech stocks with the best value, the fastest growth, and the most momentum. Early-stage biotech companies are prone to wild swings in revenue due to going from nearly no revenue to having a significant revenue stream once a drug is approved or a partnership with another company is reached. Exelixis is profitable, which enables it to use its fast-growing cash stockpile to enter into new licensing agreements and expand its drug offerings. It licenses from the development-stage biotech company Aurigene the right to develop a promising early-stage cancer drug called XL102. From WuXi Biologics, the company licenses a panel of monoclonal antibodies.

The peak annual sales forecast for AXS-07 in the U.S. alone is more than $500 million per year. Analysts think that AXS-14, if approved, could generate peak sales of between $500 million and $1 billion. The revenue potential for the three drug candidates makes Axsome Therapeutics an attractive biotech stock to consider buying in 2023. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Nabi Biopharmaceuticals is biotech’s latest stock casualty, and analysts warn not to expect a rebound any time soon.

Axsome launched Auvelity in October 2022 as a treatment for major depressive disorder. The drug, also known as AXS-05, is also being evaluated in a late-stage clinical trial targeting Alzheimer’s disease agitation and in a phase 2/3 study as a smoking cessation therapy. The biotech industry is rapidly changing in the current economic climate. Find the latest information in the newsfeed at the end of this article. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

By contrast, a biotech company is primarily research-driven. The company is using science to develop a potential therapy or vaccine. However, many of these companies are small-cap stocks that do not have a commercially used product. This means that in addition to not being profitable they are generating little to no revenue. And the small fraction of biotech companies that are profitable rarely pay a dividend.

Then you’ll need to choose between buying individual stocks or funds. He has covered investing and financial news since earning his economics degree from the University of Maryland in 2016. Sam has previously written for Investopedia, Benzinga, Seeking Alpha, Wealth Daily and Investment U, and has worked as an editor for Investment U, Wealth Daily and Haven Investment Letter. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.